Bulletin, Institute

FAST, Fellow and CARB-X Updates January 2018



FAST & Fellows Round-Up

  • Inflammatix (FAST Fall 2017), a molecular diagnostics company that is developing rapid tests that read the immune system to improve disease diagnosis, announces appointment of Oliver Liesenfeld, M.D., former CMO of Roche Molecular Diagnostics, as Chief Medical Officer Read More
  • LogicInk (FAST Spring 2017) is planning on launching its temporary tattoo-like device for recording exposure to UV radiation from the sun during the second quarter of this year Read More
  • Eidos Therapeutics (FAST Spring 2016) presented at the JP Morgan Healthcare Conference on developing AG10, a novel small molecule therapeutic for treatment of transthyretin amyloidosis Read More
  • GigaGen (FAST Spring 2015) receives NIH grant to develop production technology for recombinant intravenous immunoglobulin Read More
  • Sandstone Diagnostics (FAST Fall 2013) raises $5.8 million in Series A1 Financing Read More
  • Xcell Biosciences (FAST Fall 2013) announced it has expanded its development and commercial efforts around new market opportunities in immunotherapy drug research and development Read More

CARB-X Updates

  • CARB-X is seeking to partner with additional accelerators to expand support for its growing early development antibacterial pipeline Read More
  • Powered by CARB-X company, Vedanta Biosciences was granted four new US patents expanding coverage for compositions and methods of use for therapeutics based in microbiome-derived bacterial consortia Read More. See a recent profile of Vedanta’s CEO
  • Powered by CARB-X company, VenatoRx received an award for up to $16 million from the Defense Threat Reduction Agency (DTRA) to support preclinical development of a novel, first-in-class antibiotic for biodefense applications Read More
  • Powered by CARB-X company, Antabio announced the appointment of four biotech executives to the management team Read More
  • Powered by CARB-X company, Spero Therapeutics appoints David Melnick as Chief Medical Officer to oversee clinical development and regulatory strategy Read More
  • Powered by CARB-X company, Tetraphase Pharmaceuticals promotes Larry Tsai, VP Clinical Development to Chief Medical Officer to move forward with new drug application for IV eravacycline Read More